<?xml version="1.0" encoding="UTF-8"?>
<p>In a univariate DSA, the variables with the greatest influence on the variability of the result were identified. The analyses were performed separately for triple and DAA therapies. With both treatment regimens, the variations in costs and SVR12 rates and the fibrosis/cirrhosis status had the greatest impact on the results under the Markov model (
 <xref ref-type="fig" rid="ijerph-17-00440-f004">Figure 4</xref> and 
 <xref ref-type="fig" rid="ijerph-17-00440-f005">Figure 5</xref>).
</p>
